CELCUITY INC

CELC represents the common stock of Celcuity Inc., a clinical-stage biotechnology company. The ticker trades on the Nasdaq Capital Market, allowing investors to buy and sell shares during regular U.S. market hours. As an equity security, CELC gives shareholders an ownership stake in the company, whose value is closely tied to pipeline progress and regulatory developments rather than commercial product sales.

CELC operates in the biotechnology and life sciences sector, specifically within diagnostics and targeted cancer therapies. The company focuses on developing cellular analysis technologies designed to help guide treatment decisions for cancer patients. Because it is a clinical-stage business, industry dynamics such as clinical trial timelines, FDA review processes, and laboratory reimbursement trends can meaningfully influence how investors assess CELC.

CELC tends to be more volatile than large, diversified companies because it is a clinical-stage biotech with no commercial revenue. Share price can react sharply to clinical trial data, regulatory news, or financing announcements. For the latest volatility readings, 52-week range, and daily price swings, refer to the current CELC quote and performance data displayed on this page.

Traditional valuation metrics like P/E ratios are often less useful for clinical-stage biotechs such as CELC, since they may have limited or no earnings. Investors commonly look at cash balances, projected cash runway, enterprise value, and pipeline milestones instead. Comparing CELC's market capitalization and cash position to peers can offer context, but current valuation figures should always be checked using the latest market data shown on this page.

CELC shares can be traded in pre-market and after-hours sessions through many brokers, though liquidity is typically thinner and spreads wider than during regular Nasdaq hours. Extended-hours trading carries additional risks, including larger price swings and reduced order execution. For specific session times and any available extended-hours quotes, please refer to the trading information presented on this CELC page.

Key risks for CELC include clinical trial failure, regulatory delays, reliance on future financing, competition from other diagnostics and oncology companies, and the possibility of reimbursement challenges. As a clinical-stage company, it may operate without consistent product revenue, which can amplify share price volatility. These factors mean CELC's value is closely tied to scientific and regulatory outcomes rather than current commercial performance.